Literature DB >> 28574157

Diffuse myocardial fibrosis among healthy pediatric heart transplant recipients: Correlation of histology, cardiovascular magnetic resonance, and clinical phenotype.

Brian Feingold1,2, Cláudia M Salgado3, Miguel Reyes-Múgica3, Stacey E Drant1, Susan A Miller1, Mark Kennedy4, Peter Kellman5, Erik B Schelbert2,4,6, Timothy C Wong4,6.   

Abstract

Fibrosis is commonly described in heart allografts lost late after transplantation. CMR-derived ECV is a validated measure of DMF in native adult hearts that may predict heart failure and mortality. We explored associations of ECV with histologic myocardial fibrosis and clinical features after pediatric heart transplantation. Twenty-five recipients (7.0±6.3 years at transplant and 10.7±6.5 years post-transplant) were prospectively recruited for CMR and BNP measurement at the time of surveillance biopsy. All had normal ejection fractions and lacked heart failure symptoms. Fibrosis was quantified on biopsy after picrosirius red staining as CVF. ECV was quantified using contemporaneous hematocrit on basal and mid-short-axis slices. ECV was moderately correlated with CVF (r=.47; P=.019). We found no associations of ECV with hemodynamics, ischemic time, time since transplantation, or number of prior biopsies or acute rejections. Compared to healthy non-transplant controls, there was no significant difference in ECV (25.1±3.0 vs 23.7±2.0%, P=.09). Log-transformed BNP was correlated with ECV (recipients: r=.46, P=.02; recipients and controls: r=.45, P=.006). These findings suggest ECV quantifies DMF and relates to biological indicators of cardiac function after pediatric heart transplantation.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  allograft survival; cardiac magnetic resonance imaging; chronic rejection; extracellular volume; fibrosis; heart transplantation; interstitium; pediatric

Mesh:

Year:  2017        PMID: 28574157     DOI: 10.1111/petr.12986

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  6 in total

1.  Non-invasive detection of myocardial fibrosis in pediatric heart transplant recipients: The role of cardiovascular magnetic resonance.

Authors:  Jonathan H Soslow; Justin Godown
Journal:  Pediatr Transplant       Date:  2017-08

2.  CMR-derived extracellular volume fraction (ECV) in asymptomatic heart transplant recipients: correlations with clinical features and myocardial edema.

Authors:  Yating Yuan; Jie Cai; Yue Cui; Jing Wang; Osamah Alwalid; Xuehua Shen; Yukun Cao; Yan Zou; Bo Liang
Journal:  Int J Cardiovasc Imaging       Date:  2018-07-28       Impact factor: 2.357

Review 3.  Multi-modal imaging of the pediatric heart transplant recipient.

Authors:  Jonathan H Soslow; Margaret M Samyn
Journal:  Transl Pediatr       Date:  2019-10

4.  Donor and Recipient Characteristics in Heart Transplantation Are Associated with Altered Myocardial Tissue Structure and Cardiac Function.

Authors:  Ryan S Dolan; Amir A Rahsepar; Julie Blaisdell; Roberto Sarnari; Kambiz Ghafourian; Jane E Wilcox; Sadiya S Khan; Esther E Vorovich; Jonathan D Rich; Clyde W Yancy; Allen S Anderson; James C Carr; Michael Markl
Journal:  Radiol Cardiothorac Imaging       Date:  2019-12-19

5.  Cardiac amyloidosis is prevalent in older patients with aortic stenosis and carries worse prognosis.

Authors:  João L Cavalcante; Shasank Rijal; Islam Abdelkarim; Andrew D Althouse; Michael S Sharbaugh; Yaron Fridman; Prem Soman; Daniel E Forman; John T Schindler; Thomas G Gleason; Joon S Lee; Erik B Schelbert
Journal:  J Cardiovasc Magn Reson       Date:  2017-12-07       Impact factor: 5.364

6.  Multi-parametric cardiovascular magnetic resonance with regadenoson stress perfusion is safe following pediatric heart transplantation and identifies history of rejection and cardiac allograft vasculopathy.

Authors:  Nazia Husain; Kae Watanabe; Haben Berhane; Aditi Gupta; Michael Markl; Cynthia K Rigsby; Joshua D Robinson
Journal:  J Cardiovasc Magn Reson       Date:  2021-11-22       Impact factor: 5.364

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.